Emer O. Hanrahan

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

Ana M. González-Angulo, Jennifer K. Litton, Kristine Broglio et al. · Journal of Clinical Oncology · 2009 · 464 citations · Full text

Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma

Emer O. Hanrahan, Ana M. González-Angulo, Sharon H. Giordano et al. · Journal of Clinical Oncology · 2007 · 351 citations

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rafael Rosell, Urania Dafni, Enriqueta Felip et al. · The Lancet Respiratory Medicine · 2017 · 182 citations

Medicine, Pathology, Immune Checkpoint Inhibitor +6

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

Emer O. Hanrahan, Heather Lin, Edward S. Kim et al. · Journal of Clinical Oncology · 2009 · 131 citations · Full text

Rapid Needle-Out Patient-Rollover Time after Percutaneous CT-guided Transthoracic Biopsy of Lung Nodules: Effect on Pneumothorax Rate

Ailbhe C. O’Neill, C. F. McCarthy, Carole A. Ridge et al. · Radiology · 2011 · 94 citations